{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:54:40Z","timestamp":1790884480554,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The pathophysiology of distal symmetric polyneuropathy (DSPN) is multifactorial, involving chronic hyperglycemia, oxidative stress, accumulation of advanced glycation end products, impaired microvascular perfusion, metabolic toxicity, and nutritional deficiencies. Although previous studies have identified various risk factors, substantial heterogeneity exists across regions and populations, and most investigations have not comprehensively integrated metabolic markers, microvascular damage, and electrophysiological data. Therefore, a multidimensional assessment of DSPN risk factors is essential to improve early screening and risk-prediction strategies. A total of 120 patients with type 2 diabetes mellitus (T2DM) were enrolled, including 60 with DSPN and 60 without. Compared with the non-DSPN group, patients with DSPN were older, had longer diabetes duration, and demonstrated a higher prevalence of smoking, diabetic retinopathy (DR), and diabetic kidney disease. DSPN patients exhibited poorer glycemic control (higher fasting blood glucose, 2-hour postprandial blood glucose, and hemoglobin A1c [HbA1c]), more pronounced dyslipidemia (elevated triglycerides, reduced high-density lipoprotein cholesterol), and abnormalities in inflammatory and nutritional markers (elevated C-reactive protein and homocysteine [HCY], reduced vitamin B12). Renal function parameters (serum creatinine, estimated glomerular filtration rate, urine albumin\u2013creatinine ratio) indicated more severe microvascular impairment in the DSPN group. Electrophysiological testing showed reduced sensory and motor nerve conduction velocities, decreased amplitudes, and prolonged latencies. Multivariable logistic regression identified diabetes duration, DR, elevated HbA1c, elevated HCY, and reduced sural nerve amplitude as independent risk factors for DSPN. Longer diabetes duration, DR, elevated HbA1c, elevated HCY levels, and reduced sural nerve amplitude were independently associated with DSPN in patients with T2DM. These findings may contribute to improved risk stratification and support further investigation of multidimensional approaches for early DSPN identification. This single-center retrospective cohort study included patients with T2DM treated at our hospital between June 2023 and June 2025. DSPN was diagnosed based on American Diabetes Association, European Federation of Neurological Societies, and diabetic neuropathy working group criteria using a combination of clinical symptoms, neurological signs, and nerve conduction studies. Demographic characteristics, lifestyle factors, diabetes-related complications, glucose and lipid metabolism indicators, renal function, inflammatory and nutritional markers, and electrophysiological parameters were collected. Group differences were assessed using the\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -test, Mann\u2013Whitney\n                      <jats:italic toggle=\"yes\">U<\/jats:italic>\n                      test, or\n                      <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      test. Variables with\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.10 in univariate analyses were entered into multivariable logistic regression to identify independent risk factors for DSPN. Sensitivity analyses and collinearity diagnostics were performed to assess the robustness of the findings.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049467","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:02:12Z","timestamp":1783720932000},"page":"e49467","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors for distal symmetric polyneuropathy in patients with type 2 diabetes mellitus: A retrospective study"],"prefix":"10.1097","volume":"105","author":[{"given":"Ling","family":"Yang","sequence":"first","affiliation":[{"name":"Endocrinology department, The Lichuan Ethnic Hospital of Traditional Chinese Medicine, Lichuan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rensheng","family":"Deng","sequence":"additional","affiliation":[{"name":"Endocrinology department, Enshi Tujia and Miao Autonomous Prefecture Central Hospital, Enshi Tujia and Miao Autonomous Prefecture, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9859-9425","authenticated-orcid":false,"given":"Liling","family":"Chen","sequence":"additional","affiliation":[{"name":"Endocrinology department, Xiantao First People\u2019s Hospital, Xiantao, Hubei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2337\/dc10-1303","article-title":"Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments.","volume":"33","author":"Tesfaye","year":"2010","journal-title":"Diabetes Care"},{"key":"R2-20261001","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11892-019-1212-8","article-title":"Epidemiology of peripheral neuropathy and lower extremity disease in diabetes.","volume":"19","author":"Hicks","year":"2019","journal-title":"Curr Diab Rep"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2337\/dc11-1108","article-title":"Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K.","volume":"34","author":"Abbott","year":"2011","journal-title":"Diabetes Care"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/B978-0-444-53480-4.00008-4","article-title":"Diabetic neuropathy and foot complications.","volume":"126","author":"Boulton","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"R5-20261001","first-page":"25","article-title":"Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes clinic-based study.","volume":"27","author":"Al-Mahroos","year":"2007","journal-title":"Ann Saudi Med"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-med-043021-033114","article-title":"Spectrum of diabetic neuropathy: new insights in diagnosis and treatment.","volume":"75","author":"Dillon","year":"2024","journal-title":"Annu Rev Med"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12020-013-0136-3","article-title":"Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy.","volume":"47","author":"Sayin","year":"2014","journal-title":"Endocrine"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11892-015-0671-9","article-title":"Mitochondrial dysfunction in diabetic neuropathy: a series of unfortunate metabolic events.","volume":"15","author":"Fernyhough","year":"2015","journal-title":"Curr Diab Rep"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"561","DOI":"10.7326\/0003-4819-122-8-199504150-00001","article-title":"The effect of intensive diabetes therapy on the development and progression of neuropathy. The diabetes control and complications trial research group.","volume":"122","year":"1995","journal-title":"Ann Intern Med"},{"issue":"2_suppl","key":"R10-20261001","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/2047487319878371","article-title":"Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications.","volume":"26","author":"Dal Canto","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"R11-20261001","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4093\/dmj.2020.0100","article-title":"Study on risk factors of peripheral neuropathy in type 2 diabetes mellitus and establishment of prediction model.","volume":"45","author":"Wu","year":"2021","journal-title":"Diabetes Metab J"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy.","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","article-title":"Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy.","volume":"66","author":"Goldney","year":"2023","journal-title":"Diabetologia"},{"key":"R14-20261001","first-page":"732","article-title":"[Metabolic complications and neurologic manifestations of vitamin B12 deficiency in children of vegetarian mothers].","volume":"140","author":"Smolka","year":"2001","journal-title":"Cas Lek Cesk"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/01.wnl.0000336345.70511.0f","article-title":"Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review) [RETIRED]. Report of the American academy of neurology, American association of neuromuscular and electrodiagnostic medicine, and American academy of physical medicine and rehabilitation.","volume":"72","author":"England","year":"2009","journal-title":"Neurology"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1001\/jama.2015.13611","article-title":"Distal symmetric polyneuropathy: a review.","volume":"314","author":"Callaghan","year":"2015","journal-title":"JAMA"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1474-4422(12)70065-0","article-title":"Diabetic neuropathy: clinical manifestations and current treatments.","volume":"11","author":"Callaghan","year":"2012","journal-title":"Lancet Neurol"},{"key":"R18-20261001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-3476(94)70190-3","article-title":"Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. Diabetes control and complications trial research group.","volume":"125","year":"1994","journal-title":"J Pediatr"},{"key":"R19-20261001","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2337\/diacare.29.02.06.dc05-1549","article-title":"Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion.","volume":"29","author":"Martin","year":"2006","journal-title":"Diabetes Care"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1210\/er.2003-0019","article-title":"Oxidative stress in the pathogenesis of diabetic neuropathy.","volume":"25","author":"Vincent","year":"2004","journal-title":"Endocr Rev"},{"key":"R21-20261001","doi-asserted-by":"crossref","first-page":"e70003","DOI":"10.1002\/cph4.70003","article-title":"Type 2 diabetes mellitus: a comprehensive review of pathophysiology, comorbidities, and emerging therapies.","volume":"15","author":"Singh","year":"2025","journal-title":"Compr Physiol"},{"key":"R22-20261001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/NRL.0b013e31815a3956","article-title":"Impaired glucose tolerance and neuropathy.","volume":"14","author":"Smith","year":"2008","journal-title":"Neurologist"},{"key":"R23-20261001","doi-asserted-by":"crossref","first-page":"c2181","DOI":"10.1136\/bmj.c2181","article-title":"Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial.","volume":"340","author":"de Jager","year":"2010","journal-title":"BMJ"},{"key":"R24-20261001","first-page":"294","article-title":"Vitamin B12 deficiency: common questions and answers.","volume":"112","author":"Patel","year":"2025","journal-title":"Am Fam Physician"},{"key":"R25-20261001","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/092986710790149774","article-title":"Elevated homocysteine levels in parkinson\u2019s disease: is there anything besides L-dopa treatment?","volume":"17","author":"Zoccolella","year":"2010","journal-title":"Curr Med Chem"},{"key":"R26-20261001","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.pop.2021.11.008","article-title":"Diabetes-related microvascular complications - a practical approach.","volume":"49","author":"Mishriky","year":"2022","journal-title":"Prim Care"},{"key":"R27-20261001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-019-0092-1","article-title":"Diabetic neuropathy.","volume":"5","author":"Feldman","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2008.05.005","article-title":"Diabetic neuropathy: mechanisms to management.","volume":"120","author":"Edwards","year":"2008","journal-title":"Pharmacol Ther"},{"key":"R29-20261001","first-page":"CD004572","article-title":"Aldose reductase inhibitors for the treatment of diabetic polyneuropathy.","volume":"2007","author":"Chalk","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"R30-20261001","doi-asserted-by":"crossref","first-page":"e3702","DOI":"10.1002\/dmrr.3702","article-title":"Prevalence and risk factors of diabetic peripheral neuropathy: a population-based cross-sectional study in China.","volume":"39","author":"Wang","year":"2023","journal-title":"Diabetes Metab Res Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:01:43Z","timestamp":1790881303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":30,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049467","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"2026-01-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}